ArticlePloS one2022

Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.

Hyun Young Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.